Similar to this time last year, when IPOs were capturing everyone’s attention, M&A in biotech has been delivering real value. This morning HBM Partners released their outstanding report on BioPharma M&A in 2014 (here), and the conclusions are in line with the positive cadence and tenor of today’s excitement in the biotech market.
February 3, 2015 | LifeSciVC
Data Snapshot: VC-Backed BioPharma M&A 2014
January 30, 2015 | From the Trenches
Infusing Biotech With Young Blood
Youth is often well represented among entrepreneurs – except in biotech.
William Osler, founder of Johns Hopkins University and the alleged “Father of Modern Medicine” considered youth an asset: he said the most “effective, moving, vitalizing work of the world is done between the ages of 25 and 40 — these fifteen golden years of plenty.” (He also added that “men above 40 are relatively useless,” but out of respect for Bruce’s most recent birthday, we’ll leave this comment untouched.)
This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC.
January 22, 2015 | LifeSciVC
Venture-Backed Biotech Today: Reflections On Exits, Funding, and Startup Formation
Biotech is definitely red-hot, and has been for the past eight quarters. Immuno-oncology, cancer metabolism, gene therapy, orphan diseases, NASH, autoimmune – there’s a broad range of disease settings that are capturing the excitement and imagination of investors today.
January 20, 2015 | From the Trenches
Persistent Vitality At #JPM15
“Vitality shows in not only the ability to persist but the ability to start over.”
— F. Scott Fitzgerald
A favorite quote from the Jazz Age king that nicely captures life as a biotech entrepreneur.
This blog was written by Kevin Pojasek, Founder and acting CEO of Quartet Medicine, as part of the “From the Trenches” feature of LifeSciVC.
January 9, 2015 | LifeSciVC
Things I Expect To Hear At #JPM15
Are you ready for the circus? Next week’s JPM Healthcare Conference is getting ready to kickoff, and much of the healthcare industry is feverishly preparing their materials for the mayhem.
Given the biopharma industry pipeline’s exciting clinical progress, a record-breaking year of FDA approvals, a buoyant stock market, and 2014’s chart-topping biotech IPO volume – it’s bound to be a positive and optimistic kickoff to the year.